Shares in Genmab A/S slid more than 20 percent Monday on news that zalutumumab, an antibody-targeting epidermal growth factor receptor (EGFR), failed to reach the primary endpoint of a pivotal Phase III trial in head and neck cancer. (BioWorld Today)

A ray of light recently pierced the gloom surrounding Basilea Pharmaceutica AG's program for its cephalosporin antibiotic ceftobiprole (Zevtera), which is in development for complicated skin and soft tissue infections. (BioWorld International)